中國飛鶴(06186.HK)漏報65億人幣認購金融產品
中國飛鶴(06186.HK)公布,於2021年及2022年認購中信銀行(00998.HK)及建設銀行(00939.HK)發行的理財及結構性存款金融產品,涉資約65.05億元人民幣。就上市規則而言,若干中信銀行及建設銀行的認購事項按未贖回本金金額單獨或累計計算構成公司須予披露交易,惟集團未及時遵守上市規則。
集團指,對未能遵守上市規則深表歉意,但謹此強調,該違規行為屬無心之失,並非有意為之。公司無意隱瞞與認購事項有關的任何信息,不向公眾披露。為防止日後發生類似情況,已對認購理財及結構性存款金融產品進行全面審閱及檢查,並加強對公司財務部門負責人員的培訓等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.